AnaptysBio (NASDAQ:ANAB) Raised to Hold at Truist Financial

AnaptysBio (NASDAQ:ANAB) was upgraded by equities researchers at Truist Financial to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. UBS Group boosted their target price on AnaptysBio from $70.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. HC Wainwright increased their price target on AnaptysBio from $51.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Stifel Nicolaus lifted their price objective on AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Barclays boosted their price objective on AnaptysBio from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $78.44.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $64.99 on Wednesday. The company has a market capitalization of $1.87 billion, a PE ratio of -124.98 and a beta of 0.32. AnaptysBio has a 52-week low of $15.40 and a 52-week high of $68.39. The company has a 50-day simple moving average of $55.06 and a 200 day simple moving average of $43.24.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The firm had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. As a group, analysts forecast that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In related news, insider Paul F. Lizzul sold 4,219 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $43.26, for a total transaction of $182,513.94. Following the sale, the insider directly owned 33,303 shares in the company, valued at approximately $1,440,687.78. The trade was a 11.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Faga sold 15,309 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $662,267.34. Following the sale, the chief executive officer directly owned 458,139 shares in the company, valued at $19,819,093.14. This trade represents a 3.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 92,514 shares of company stock valued at $4,243,935. 33.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC raised its position in shares of AnaptysBio by 1.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 225 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in AnaptysBio by 24.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 263 shares in the last quarter. Larson Financial Group LLC increased its stake in AnaptysBio by 21.2% in the fourth quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 284 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its position in AnaptysBio by 1.4% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock valued at $1,743,000 after purchasing an additional 500 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.